Via Email

Single Technology Appraisal
Erlotinib for the treatment of non-small cell lung cancer

Dear Consultee or Commentator,

With reference to the decision of the Appeal Panel on the appraisal of erlotinib for the treatment of patients with non-small cell lung cancer (sent to you on 26 September 2007) the Institute is seeking further evidence to inform future deliberations of the Appraisal Committee.

Specifically, the Institute is seeking submissions from consultees and commentators detailing the following:

- The range of estimates for the incidence of febrile neutropenia in non-small cell lung cancer patients who are receiving docetaxel; from the literature and from current NHS practice.
- The range of estimates for resources required and associated cost of treating febrile neutropenia in line with standard NHS practice in England and Wales (including the extent of the use of granulocyte-colony stimulating factor).

Your submission is gladly received at the earliest available opportunity but no later than 5pm on Thursday 18 October 2007.

Please submit your response via email to Christopher Feinmann, Project Manager on christopher.feinmann@nice.org.uk. If you have any technical queries, please contact Dr Louise Longworth, Technical Advisor, on louise.longworth@nice.org.uk.
The Appeal Panel has also asked the Institute to inform you of the curve-scanning software that was used by the Evidence Review Group during the appraisal. The software used was TechDig® 2.0.

Yours sincerely,

Meindert Boysen
Associate Director STA
Centre for Health Technology Evaluation